Viral Dynamic Surveillance in COVID-19 Patients: A Cohort Study

DeWu Bi,ZhenCheng Chen,ShanQiu Wei,ZhouHua Xie,Ning Zang,LiDa Mo,ZeDuan Liu,YuanLi Wang,LiangLi Cao,FeiJun Zhao,YanRong Lin,YaQin Qin,XiKe Tang,HanZhen Su,JinAi Zhou,JuanYing Liang,ZhenXu Lan,Lue Lin,ShaoYong Xi,XiaoCheng Luo,QiuYing Ma,XiaoFeng Pang,XiaoLu Luo
DOI: https://doi.org/10.1155/2022/1399268
2022-01-01
BioMed Research International
Abstract:Background Coronavirus disease 2019 (COVID-19) is a potentially fatal pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially those of novel SARS-CoV-2 variants and infection has affected over 700 million people globally. Methods This retrospective, descriptive study included 118 patients admitted with SARS-CoV-2 infection as confirmed by real-time reverse transcription polymerase chain reaction. Results The median duration of detectable SARS-CoV-2 infection in patients with high ALT, AST, and PLT/LYMPH, or low CD4+, CD8+, and PLT/MONO was considerably longer. In the risk factor model, multivariate analysis was performed for the estimation of ALT (HR, 0.54; 95% CI, 0.36-0.81), AST (HR, 0.56; 95% CI, 0.34-0.93), CD4+ (HR,0.77; 95% CI, 0.48-1.24), CD8+ (HR,0.64; 95% CI, 0.37-1.11), PLT/LYMPH (HR, 1.16; 95% CI, 0.76-1.77), and PLT/MONO (HR, 0.64; 95% CI, 0.43-0.94). Conclusions The longer viral RNA duration was associated with a higher International Prognostic Index score (p = 0.0013), demonstrating for the first time that multivariate features of the bioindicators closely associated with SARS-CoV-2-infected patients clear the virus.
What problem does this paper attempt to address?